Teva chief reports 'strong progress' in restructuring plan | The Times of Israel
Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes - Bloomberg
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026 | Business Wire
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva Shakes Up C-Suite in Restructuring | BioSpace
Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes - Bloomberg
S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable
Moody's upgrades Teva's rating outlook - Globes
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Sell Teva Pharmaceutical due to increasing generic drugs competition: Credit Suisse
Teva Pharmaceutical Industries Limited Credit Ratings :: Fitch Ratings
Teva Hits FDA Hurdle, Slips 4.5% Pre-Market - TipRanks.com
Rating Agencies Exacerbate The Covid Crisis for Sovereigns - Track Live Bond Prices Online with BondEValue App - credit downgrades, credit ratings, sovereign bonds, sovereign ratings
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Teva Pharmaceutical Stock: Hinting A Payoff Potential (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical S&P rating outlook changed to stable | Seeking Alpha
S&P cuts Teva's rating on rising litigation risks - Globes
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Why Teva's Stock Could Crash Another 50% | BioSpace
Moody's Downgrades Teva Bond Rating to “Junk” | Ctech
Teva Pharmaceutical Industries Ltd (ADR) Needs More Than Job Cuts
Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
